Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H12FN3 |
Molecular Weight | 265.285 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CN2C=C(CCC#CC3=NC=CC=C3)N=C2C=C1
InChI
InChIKey=LZXMUJCJAWVHPZ-UHFFFAOYSA-N
InChI=1S/C16H12FN3/c17-13-8-9-16-19-15(12-20(16)11-13)7-2-1-5-14-6-3-4-10-18-14/h3-4,6,8-12H,2,7H2
DescriptionCurator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800026607 | https://www.ncbi.nlm.nih.gov/pubmed/27214664 | https://www.ncbi.nlm.nih.gov/pubmed/24951854
Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800026607 | https://www.ncbi.nlm.nih.gov/pubmed/27214664 | https://www.ncbi.nlm.nih.gov/pubmed/24951854
Dipraglurant (ADX48621) is a novel, potent mGluR5 negative allosteric modulator that reduced the severity of drug-induced dyskinesia in Parkinson's disease. Dipraglurant pharmacokinetic variables were similar to those of levodopa, suggesting that both drugs can be co-administered simultaneously in further studies. Dipraglurant might be useful in torsion dystonia treatment also. Detected adverse events are: sweating, dyskinesia, nausea, dizziness, and anxiety. One serious adverse event described as possible syncope.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3227 Sources: http://adisinsight.springer.com/drugs/800026607 |
0.021 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
679.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27214664 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPRAGLURANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1320.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27214664 |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DIPRAGLURANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1521 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27214664 |
300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DIPRAGLURANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
858.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27214664 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPRAGLURANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1760.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27214664 |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DIPRAGLURANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2009.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27214664 |
300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DIPRAGLURANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27214664 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPRAGLURANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.67 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27214664 |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DIPRAGLURANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.65 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27214664 |
300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DIPRAGLURANT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg 3 times / day multiple, oral (unknown) Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy n = 76 Health Status: unhealthy Condition: Parkinson disease Sex: M+F Food Status: UNKNOWN Population Size: 76 Sources: |
Disc. AE: Sweating, Dyskinesia... AEs leading to discontinuation/dose reduction: Sweating (1 pt) Sources: Dyskinesia (1 pt) Nausea (1 pt) Dizziness (1 pt) Anxiety (1 pt) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Anxiety | 1 pt Disc. AE |
100 mg 3 times / day multiple, oral (unknown) Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy n = 76 Health Status: unhealthy Condition: Parkinson disease Sex: M+F Food Status: UNKNOWN Population Size: 76 Sources: |
Dizziness | 1 pt Disc. AE |
100 mg 3 times / day multiple, oral (unknown) Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy n = 76 Health Status: unhealthy Condition: Parkinson disease Sex: M+F Food Status: UNKNOWN Population Size: 76 Sources: |
Dyskinesia | 1 pt Disc. AE |
100 mg 3 times / day multiple, oral (unknown) Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy n = 76 Health Status: unhealthy Condition: Parkinson disease Sex: M+F Food Status: UNKNOWN Population Size: 76 Sources: |
Nausea | 1 pt Disc. AE |
100 mg 3 times / day multiple, oral (unknown) Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy n = 76 Health Status: unhealthy Condition: Parkinson disease Sex: M+F Food Status: UNKNOWN Population Size: 76 Sources: |
Sweating | 1 pt Disc. AE |
100 mg 3 times / day multiple, oral (unknown) Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy n = 76 Health Status: unhealthy Condition: Parkinson disease Sex: M+F Food Status: UNKNOWN Population Size: 76 Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27214664
50 mg once daily up to 100 mg three times daily, at the start of week 4
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24951854
The presence of 1 mM dipraglurant the response to D2R was unaltered, both 3 and 10 mM dose-dependently reduced the increase in both firing rate and [Ca2+]i induced by quinpirole (10 mM) in Tor1a(+/Δgag) interneurons.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
485215
Created by
admin on Sat Dec 16 16:47:04 GMT 2023 , Edited by admin on Sat Dec 16 16:47:04 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000034194
Created by
admin on Sat Dec 16 16:47:04 GMT 2023 , Edited by admin on Sat Dec 16 16:47:04 GMT 2023
|
PRIMARY | |||
|
872363-17-2
Created by
admin on Sat Dec 16 16:47:04 GMT 2023 , Edited by admin on Sat Dec 16 16:47:04 GMT 2023
|
PRIMARY | |||
|
CHEMBL2346738
Created by
admin on Sat Dec 16 16:47:04 GMT 2023 , Edited by admin on Sat Dec 16 16:47:04 GMT 2023
|
PRIMARY | |||
|
C171677
Created by
admin on Sat Dec 16 16:47:04 GMT 2023 , Edited by admin on Sat Dec 16 16:47:04 GMT 2023
|
PRIMARY | |||
|
DTXSID90236230
Created by
admin on Sat Dec 16 16:47:04 GMT 2023 , Edited by admin on Sat Dec 16 16:47:04 GMT 2023
|
PRIMARY | |||
|
CV8JZR21A1
Created by
admin on Sat Dec 16 16:47:04 GMT 2023 , Edited by admin on Sat Dec 16 16:47:04 GMT 2023
|
PRIMARY | |||
|
Dipraglurant
Created by
admin on Sat Dec 16 16:47:04 GMT 2023 , Edited by admin on Sat Dec 16 16:47:04 GMT 2023
|
PRIMARY | |||
|
44557636
Created by
admin on Sat Dec 16 16:47:04 GMT 2023 , Edited by admin on Sat Dec 16 16:47:04 GMT 2023
|
PRIMARY | |||
|
9180
Created by
admin on Sat Dec 16 16:47:04 GMT 2023 , Edited by admin on Sat Dec 16 16:47:04 GMT 2023
|
PRIMARY | |||
|
DB12733
Created by
admin on Sat Dec 16 16:47:04 GMT 2023 , Edited by admin on Sat Dec 16 16:47:04 GMT 2023
|
PRIMARY |
ACTIVE MOIETY